Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24337779 | 0.75 | CYP2C19 (0.48) | ALDH1A1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL29654797 | 0.75 | CYP2C19 (0.48) | ALDH1A1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL15471054 | 0.74 | ALDH1A1 (0.69) | ALDH1A1KMT2ALMNASMN1; SMN2RAB9A | |
| SCHEMBL6520496 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2ALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL13934757 | 0.72 | GAA (0.53) | ALDH1A1KMT2ALMNATSHRKDM4E | |
| SCHEMBL4527439 | 0.72 | GAA (0.53) | ALDH1A1KMT2ALMNATSHRKDM4E | |
| SCHEMBL29657316 | 0.72 | PKM (0.61) | ALDH1A1KMT2ALMNATSHRKDM4E | |
| SCHEMBL31629999 | 0.72 | PKM (0.61) | ALDH1A1KMT2ALMNATSHRKDM4E | |
| SCHEMBL15471052 | 0.72 | ALDH1A1 (0.65) | ALDH1A1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL30471853 | 0.72 | ALDH1A1 (0.57) | ALDH1A1KMT2ALMNAGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | ALDH1A1 991/4885KMT2A 1990/4885LMNA 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.